Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANEB 
Anebulo Pharmaceuticals Inc (ANEB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ANEB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.73% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 102.30M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta -0.89 | 52 Weeks Range 0.80 - 3.42 | Updated Date 09/17/2025 |
52 Weeks Range 0.80 - 3.42 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date 2025-09-17 | When - | Estimate -0.05 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.45% | Return on Equity (TTM) -83.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 89021079 | Price to Sales(TTM) - |
Enterprise Value 89021079 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.54 | Shares Outstanding 41084700 | Shares Floating 3401405 |
Shares Outstanding 41084700 | Shares Floating 3401405 | ||
Percent Insiders 40.54 | Percent Institutions 54.99 |
Upturn AI SWOT
Anebulo Pharmaceuticals Inc
Company Overview
History and Background
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel solutions for substance abuse. Founded in 2014, they are primarily focused on developing treatments to reverse the effects of cannabinoid intoxication and overdose.
Core Business Areas
- Drug Development: Anebulo develops and researches pharmaceutical products, with a primary focus on treatments for cannabinoid overdose and related conditions.
Leadership and Structure
Dr. Joseph Perl is the CEO. The company has a typical structure for a biotech firm, with teams focused on research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- ANEB-001: Anebulo's primary product candidate is ANEB-001, a competitive antagonist designed to reverse the effects of cannabinoid intoxication. It is currently in clinical development. Market share is N/A as it is pre-market. Key competitors, if approved, would be symptomatic treatment and emergency care procedures to manage cannabinoid overdose.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. There is a growing need for treatments addressing substance abuse and overdose, particularly in the context of increasing cannabis legalization. However, the market for cannabis overdose reversal is still nascent.
Positioning
Anebulo is positioning itself as a leader in the niche market of cannabinoid intoxication reversal. Its competitive advantage lies in its novel mechanism of action for ANEB-001.
Total Addressable Market (TAM)
The TAM for cannabinoid overdose reversal is difficult to quantify due to limited data on incidence and treatment patterns. However, with increasing cannabis use, the potential market is significant. Anebulo is positioning itself to capture a significant share if ANEB-001 is approved.
Upturn SWOT Analysis
Strengths
- Novel product candidate (ANEB-001)
- Focus on a specific unmet medical need (cannabinoid overdose)
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- High regulatory risk
Opportunities
- Increasing cannabis legalization leading to higher overdose rates
- Potential for FDA approval and market exclusivity
- Partnerships with larger pharmaceutical companies
Threats
- Failure of clinical trials
- Competition from other treatments or therapies
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
Competitive Landscape
Anebulo has no direct publicly traded competitor focused solely on cannabinoid overdose reversal. However, companies developing treatments for substance abuse represent indirect competition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as it is a clinical-stage company without commercial products.
Future Projections: Future growth depends on successful clinical trials and regulatory approval of ANEB-001. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Recent initiatives include progressing ANEB-001 through clinical trials and seeking partnerships.
Summary
Anebulo Pharmaceuticals is a high-risk, high-reward clinical-stage biotech company focused on an unmet medical need. The company's success hinges on the successful development and commercialization of ANEB-001. Its early stage means it is highly speculative and success is tied to the drug progress. Funding and drug trial results will be the key indicator of success or failure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. The information provided is based on publicly available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anebulo Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Lakeway, TX, United States | ||
IPO Launch date 2021-05-07 | CEO & Director Mr. Richard Anthony Cunningham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.anebulo.com |
Full time employees 2 | Website https://www.anebulo.com | ||
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.